INTERIM REPORT
1 JANUARY – 30 SEPTEMBER 2021
We strive to improve people's lives
SEK 1,850 m
NET SALES
SEK 286 m
EBITA
114 %
EARNINGS GROWTH R12 MONTHS
105 %
P/WC
Another strong quarter
After almost two years of the COVID-19 pandemic, our communities are starting to re-open. The business situation in the third quarter remained favourable, influenced by the efforts of the different countries to manage the infection. Sales in the third quarter increased by 49 percent to SEK 1,850 million and the result, EBITA, increased by 44 percent to SEK 286 million and the EBITA margin amounted to 15.5 percent. Accumulated for the interim period, sales increased by 65 percent to SEK 5,862 million and EBITA rose by 94 percent to SEK 944 million.
A leading player in Life Science
AddLife is a listed Swedish Medtech company active on the European market. AddLife owns and acquires companies in niche segments with offerings aimed primarily at the healthcare sector, from research to medical care. The subsidiaries are divided into two business areas. Labtech offers products, solutions and a wide range of diagnostic services, biomedical research and laboratory analysis. Medtech offers products, solutions and services in medical technology and home care.
Increased acquisition activity through three strategic acquisitions during the interim period
In 2021, we completed three acquisitions with total expected annual sales of about SEK 2,540 million and we welcomed 671 employees to the Group. This quarter we continued our European expansion through the acquisition of the Bio-Connect Group to Labtech. The acquisitions make AddLife a true European player with more than half of net sales in markets outside the Nordic region.
